Titre
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Wen Patrick, Y.
Auteure/Auteur
Macdonald David, R.
Auteure/Auteur
Reardon David, A.
Auteure/Auteur
Cloughesy Timothy, F.
Auteure/Auteur
Sorensen A. Gregory,
Auteure/Auteur
Galanis, Evanthia
Auteure/Auteur
DeGroot, John
Auteure/Auteur
Wick, Wolfgang
Auteure/Auteur
Gilbert Mark, R.
Auteure/Auteur
Lassman Andrew, B.
Auteure/Auteur
Tsien, Christina
Auteure/Auteur
Mikkelsen, Tom
Auteure/Auteur
Wong Eric, T.
Auteure/Auteur
Chamberlain Marc, C.
Auteure/Auteur
Stupp, Roger
Auteure/Auteur
Lamborn Kathleen, R.
Auteure/Auteur
Vogelbaum Michael, A.
Auteure/Auteur
van den Bent Martin, J.
Auteure/Auteur
Chang Susan, M.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1527-7755[electronic], 0732-183X[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
28
Numéro
11
Première page
1963
Dernière page/numéro d’article
1972
Langue
anglais
Résumé
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.
PID Serval
serval:BIB_1316C4764D89
PMID
Date de création
2010-04-27T13:23:42.046Z
Date de création dans IRIS
2025-05-20T14:46:44Z